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Our recent studies implicated key and distinct roles for the highly related RalA and RalB small GTPases (82% sequence identity)
in pancreatic ductal adenocarcinoma (PDAC) tumorigenesis and invasive and metastatic growth, respectively. How RalB may
promote PDAC invasion and metastasis has not been determined. In light of known Ral effector functions in regulation of actin
organization and secretion, we addressed a possible role for RalB in formation of invadopodia, actin-rich membrane protrusions
that contribute to tissue invasion and matrix remodeling. We determined that a majority of KRAS mutant PDAC cell lines exhib-
ited invadopodia and that expression of activated K-Ras is both necessary and sufficient for invadopodium formation. Invado-
podium formation was not dependent on the canonical Raf-MEK-ERK effector pathway and was instead dependent on the Ral
effector pathway. However, this process was more dependent on RalB than on RalA. Surprisingly, RalB-mediated invadopodium
formation was dependent on RalBP1/RLIP76 but not Sec5 and Exo84 exocyst effector function. Unexpectedly, the requirement
for RalBP1 was independent of its best known function as a GTPase-activating protein for Rho small GTPases. Instead, disrup-
tion of the ATPase function of RalBP1 impaired invadopodium formation. Our results identify a novel RalB-mediated biochemi-
cal and signaling mechanism for invadopodium formation.
The ability of cancer cells to degrade the extracellular matrix andinvade through the basement membrane is essential for met-
astatic disease (23, 53). Pancreatic cancer is a highly aggressive and
invasive disease, though the mechanisms by which pancreatic
ductal adenocarcinoma (PDAC) cells mediate invasion and me-
tastasis are largely unknown (65). Mutational activation of K-Ras
is an early initiating event that occurs in essentially 100% of hu-
man pancreatic tumors (28). However, K-Ras activity may also
contribute to invasion and metastasis of PDAC (12), suggesting
that K-Ras plays a role in multiple steps of tumor progression.
The formation of dynamic, actin-rich, extracellular matrix-de-
grading protrusions known as invadopodia is linked to the inva-
sive phenotype of cancer cells (10, 11, 21, 66). Invadopodia have
been identified in multiple malignancies, including melanoma,
glioblastoma, breast, and head and neck squamous cell carci-
noma, and whether they are seen in PDAC has not been deter-
mined. While members of the Rho family of small GTPases (Rac1,
RhoA, and Cdc42) have been implicated in invadopodium forma-
tion (19, 37, 52), whether aberrant Ras activation can promote
invadopodium formation has not been addressed.
KRAS encodes a small GTPase that serves as a signaling node
activating multiple downstream pathways in response to extracel-
lular stimuli (18, 31). Activating mutations in KRAS encode a
constitutively activated K-Ras protein which stimulates persistent,
deregulated activation of downstream signaling pathways. The ca-
nonical effectors of Ras are the Raf serine/threonine kinases,
which phosphorylate and activate the MEK1 and MEK2 dual spec-
ificity kinases, and MEK1/MEK2 phosphorylate and activate the
ERK1/ERK2 mitogen-activated protein kinases (MAPKs) (18,
31). A second important group of effectors is the class IA catalytic
subunits of phosphoinositide 3-kinases (PI3Ks). The third-best
validated class of effectors required for Ras-mediated oncogenesis
is comprised of guanine nucleotide exchange factors (RalGEFs)
for the highly related RalA and RalB small GTPases (7, 51). In
PDAC, our studies suggest that the RalGEF-Ral effector pathway
may be more essential than Raf or PI3K signaling for mutant
KRAS-dependent tumor growth (34). Interestingly, we deter-
mined that RalA and RalB have distinct roles in PDAC, with RalA
required for anchorage-independent growth in vitro and tumori-
genic growth in vivo, whereas Matrigel invasion and lung coloni-
zation metastasis were more dependent on RalB (36). The distinct
functions of RalA and RalB are unexpected in that they can inter-
act with the same set of downstream effectors, including subunits
of the exocyst complex and the RalBP1/RLIP76 Rho GTPase-ac-
tivating protein (RhoGAP) (7, 51). Whether RalA and RalB utilize
distinct effectors to mediate their distinct functions in PDAC has
not been determined.
How RalB promotes PDAC invasion and metastasis has not
been determined. Since the effector functions of RalB can regulate
actin organization and exocytosis, activities critical for invadopo-
dium formation, we investigated whether invadopodia are associ-
ated with pancreatic cancer invasiveness and regulated by K-Ras
and Ral signaling. We determined that invadopodia are seen in a
majority of PDAC cell lines, that mutant K-Ras is necessary and
sufficient for invadopodium induction, and that the Ral effector
pathway, but not the Raf effector pathway, is required for this
activity. RalB, and to a lesser extent RalA, was required and, un-
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expectedly, did not require the exocyst and instead required
RalBP1 through a RhoGAP-independent mechanism. Instead, we
have found that the ATPase function of RalBP1 is critical for in-
vadopodia in PDAC. Our studies establish the first association for
K-Ras and RalB for invadopodium formation and establish a
novel effector function in this process.
MATERIALS AND METHODS
Human pancreatic tumor cell lines. The MIA PaCa-2, CFPAC-1,
PANC-1, Capan-1, Capan-2, Panc 10.05, and T3M4 PDAC cell lines were
obtained from the ATCC (Manassas, VA), and the HuPT3 cell line was
obtained from Dan Billadeau (Mayo Clinic, Rochester, MN). The immor-
talized human pancreatic duct-derived (HPNE) cells and the matched
K-Ras-transformed cell line (HPNE-KRAS) were described previously
(13, 33).
Plasmids and viral infection. pSUPER.retro.blast plasmids encoding
short hairpin RNA (shRNA) directed against sequences encoding green
fluorescent protein (GFP; nonspecific control) (4) or human RalA and
RalB have been validated and characterized previously (41). pBabe-puro
plasmids expressing RNA interference (RNAi)-resistant sequences en-
coding wild-type (WT) RalB or the D49N and D49E effector mutants
were used to infect PDAC cells (as described previously) (41). Blasticidin-
resistant (Invitrogen) and puromycin-resistant (Invitrogen) stable cell
lines were generated (for blasticidin, MIA PaCa-2 and Capan-2 [5 g/ml],
CFPAC-1 [10 g/ml], and PANC-1 [20 g/ml]; for puromycin, CFPAC-1
and PANC-1 [2 g/ml]). pSUPER.retro.puro plasmids encoding shRNA
directed against the coding sequence for human KRAS G12V (5=-GTTG
GAGCTGGTGGCGTAG-3=) were described previously (9). The pLKO.1
plasmid encoding nonspecific (NS) RNA (5=-CCTCTTGATGAACCATC
TATT-3=) or shRNA directed against the 3= untranslated region (UTR) of
human KRAS (5=-CAGTTGAGACCTTCTAATTGG-3=) were obtained
from Jeffrey Settleman (Charlestown, MA) and were previously described
(61). Lentiviral particles were generated using the pLKO.1 plasmid encod-
ing nonspecific (NS) RNAs and shRNAs directed against RalBP1 obtained
from Open Biosystems. The sequences for the clones are as follows: for
clone 47920, 5=-GCACAAGAGATAGCCAGTCTT-3=, and for clone
47922, 5=-GCCAGTTTGCTGAAGCAGTAT-3=. The pSUPER.retro.blast
plasmid encoding shRNA against human RalBP1 has been previously de-
scribed (26). The pBabe-HAII-puro expression plasmid encoding an
RNAi-resistant sequence for WT RalBP1 was generated by introducing
silent mutations as described previously (41). The R232A/K268A (RK/
AA) RalBP1 mutant was generated by introducing missense mutations in
two consecutive mutagenesis reactions using the following mutations
(mutated base pairs are italicized): R232A-5=-GAAGTGTGAAGGCATC
TACGCAGTATCAGGAATTAAATC-3= and K268A-5=-GTAGCCAGTT
TGCTGGCGCAGTATTTGCGAG-3=. The cDNA sequence encoding the
R208L/K244R (RK/LR) RalBP1 mutant was obtained from Christopher
Counter (Duke University) and subcloned into the pBabe-HA expression
construct. The K74M and K425M RalBP1 mutants were generated by
introducing missense mutations using the following primers (mutated
base pairs are italicized): K74M-5=-GAAGAAAAAAGGGATGTTTAAGA
AAAAGG-3= and K425M-5=-GATAAAGGATTTGTCTATGGAAGAAA
GATTATGGG-3=. The K74M/K425M RalBP1 double mutant was gener-
ated by introducing missense mutations in two consecutive reactions
using the above-described primers.
Immunoblot analyses. Whole-cell lysates were isolated in NP-40 lysis
buffer (50 mM Tris-HCl [pH 7.4], 10 mM MgCl2, 150 mM NaCl, 1%
NP-40, 10% glycerol, 0.25% sodium deoxycholate). Proteins were sepa-
rated by SDS-PAGE and transferred to Immobilon-P polyvinylidene di-
fluoride (PVDF) membranes (Millipore, Billerica, MA). Membranes were
blocked with 5% bovine serum albumin (Sigma) in Tris-buffered saline-
Tween 20 (TBST) (0.1% Tween 20) buffer, incubated with primary anti-
bodies, including mouse anti-K-Ras (clone OP24) (Millipore), mouse
anti-RalB (Millipore), mouse anti--tubulin (Sigma), mouse antivinculin
(Sigma), mouse anti--actin (Sigma), rabbit anti-phospho-ERK1/2 (Cell
Signaling Technology), rabbit anti-ERK1/2 (Cell Signaling Technology),
rabbit anti-phospho-Ser473 Akt (Cell Signaling Technology), rabbit anti-
Akt (Cell Signaling Technology), mouse anti-RalA (BD Biosciences),
mouse antihemagglutinin (anti-HA) (clone 16B12) (Covance), or mouse
anti-RalBP1 (Abnova), overnight at 4°C, washed, and incubated with spe-
cies-appropriate horseradish peroxidase-conjugated secondary antibod-
ies (Pierce). Membranes probing with anti-RalBP1 were blocked in 5%
(wt/vol) nonfat dry milk in phosphate-buffered saline–Tween 20 (PBST)
(0.1% Tween 20) as suggested by the manufacturer. Membranes were
subjected to detection using enhanced chemiluminescence.
Fluorescent matrix degradation assay. The fluorescent matrix degra-
dation assay was utilized to evaluate invadopodia and was described pre-
viously (16). Briefly, human fibronectin (BD Biosciences) was coupled to
Alexa Fluor 488 using a protein labeling kit (Invitrogen). A 50-g/ml
solution was prepared in phosphate-buffered saline (PBS) and incubated
on cross-linked gelatin (300 Bloom) (Sigma) on glass coverslips. Cover-
slips were sterilized with 70% ethanol and equilibrated with growth me-
dium for 30 min prior to adding cells. Cells were seeded on coverslips,
incubated for 24 h, fixed in 4% paraformaldehyde, permeabilized in 0.5%
Triton X-100 –PBS, and blocked in 3% bovine serum albumin–PBS. Cov-
erslips were then incubated with mouse anticortactin (clone 4F11) anti-
body (Millipore) or fluorescent phalloidin. For inhibitor experiments,
cells were seeded on the coverslips in the presence of U0126 (Sigma) or
LY294002 (Cell Signaling Technology). Confocal images were acquired
using an LSM 510 Meta laser scanning microscope (Carl Zeiss) with a
63, 1.3-numerical-aperture oil immersion lens, and images were pro-
cessed by Photoshop software (Adobe Systems).
Gelatin zymography. Cells expressing GFP (control) or RalB-specific
shRNA were seeded at 50% confluence and allowed to attach overnight.
Serum-free medium was added to the cells for 24 h, conditioned media
were collected, and cells were lysed in NP-40 lysis buffer. Protein concen-
trations for conditioned media were normalized to total cell numbers
(total protein concentration from each cell lysate) and determined using
the Bio-Rad Bradford protein assay. Nonreducing 6 Laemmli sample
buffer was added to normalized conditioned medium, and samples were
loaded onto 10% SDS-PAGE containing 0.2% gelatin (175 Bloom)
(Sigma) and run under nonreducing conditions. Gels were washed with
2.5% Triton 100-X twice for 15 min and incubated at 37°C in substrate
buffer (50 mM Tris-HCl [pH 7.5], 10 mM CaCl2) overnight, stained with
0.5% Coomassie blue, 50% methanol, and 10% acetic acid, and destained
in 50% methanol and 10% acetic acid.
Surface biotinylation and avidin pulldown. Surface biotinylation
and avidin pulldown experiments were performed using the Pierce cell
surface protein isolation kit (Pierce). Briefly, CFPAC-1 cells were seeded
on tissue culture flasks coated with 2.5% gelatin–2.5% sucrose–PBS, la-
beled with biotin, harvested, and lysed. NeutrAvidin agarose was used to
isolate biotinylated surface proteins from lysates. Eluates were loaded
onto 10% SDS-PAGE and subjected to immunoblot analysis using rabbit
anti-MT1-MMP antibody (Calbiochem).
GTP hydrolysis assay. The human RalBP1 cDNA (residues 124 to 468)
was subcloned into the NcoI and XhoI sites of the bacterial expression vector
pProEX-HTb to express an N-terminal His6-tagged recombinant RalBP1
protein. The RalBP1 protein was expressed in the Escherichia coli strain Ro-
setta 2 (DE3) for 5 h at 25°C and purified on a nickel-charged metal chelating
column (GE Healthcare), followed by separation on an S200 size exclusion
column (GE Healthcare) equilibrated in a buffer containing 50 mM Tris (pH
8.0), 200 mM NaCl, 1 mM EDTA, 2 mM dithiothreitol (DTT), and 10%
glycerol. The purified protein was concentrated to 10 mg/ml and snap-frozen
in liquid N2. Site-directed mutagenesis of pProEx-HTb RalBP1 was carried
out using the QuikChange kit (Stratagene) to replace arginine 232 and lysine
268 with alanines. RalBP1 (residues 124 to 468) R232A/K268A was expressed
and purified exactly as described above for the wild-type protein. Recombi-
nant human Cdc42 (C188S) was bacterially expressed and purified as previ-
ously described (45).
The GAP activity of RalBP1 was measured biochemically using the
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N-[2-(1-maleimidyl)ethyl]-7-(diethylamino)coumarin-3-carboxamide
(MDCC) fluorophore-tagged phosphate-binding protein (PBP) fluo-
rescent-based GAP assay as described previously (60). Briefly, Cdc42 was
preloaded with GTP in nucleotide exchange buffer (10 mM HEPES [pH
7.5], 50 mM NaCl, 5 mM EDTA, 2 mM DTT and 1 mM GTP) for 20 min
at 22°C before being stabilized with 20 mM MgCl2. GTP-loaded Cdc42
was then rapidly desalted on a PD10 column (GE Healthcare) equilibrated
in 10 mM HEPES (pH 7.5), 50 mM NaCl, 1 mM MgCl2, 5% glycerol, and
2 mM dithiothreitol to remove excess GTP. Following desalting, single-
turnover hydrolysis assays were performed with 3 M MDCC-PBP and 2
M Cdc42 in a reaction buffer containing 20 mM Tris (pH 7.5), 50 mM
NaCl, and 2 mM MgCl2. Assays were initiated with addition of 1 M
wild-type or R232A/K268A RalBP1 to the reaction buffer. The real-time
fluorescent signal (ex  425 nm, em  465 nm) of the GAP reaction was
monitored using a FluorMax 4 (Horiba) spectrofluorimeter with constant
stirring at 15°C. An increase in fluorescence corresponds to a proportional
increase in Pi production from GTP hydrolysis. The data were graphed in
GraphPad Prism.
RESULTS
KRAS mutant pancreatic carcinoma cells form invadopodia.
The signaling mechanisms that drive PDAC invasion and metas-
tasis remain poorly characterized. Since the formation of invado-
podia is associated with the invasive and metastatic potential of
breast and other cancers, we first addressed the possibility that
these structures are also found in PDAC cells. A panel of eight
PDAC cell lines was analyzed for invadopodium activity using a
fluorescent matrix degradation assay. Cells were seeded on fluo-
rescently labeled fibronectin, and areas of matrix degradation that
overlapped with anti-cortactin staining were identified as active
invadopodia and scored. The majority of the cell lines analyzed
exhibited moderate (more than 1 invadopodium per cell, percent-
age of invadopodium-positive cells per field of greater than 30%)
to high (more than 3 invadopodia per cell, percentage of invado-
podium-positive cells per field of greater than 40%) invadopo-
dium activity (Fig. 1).
Activated K-Ras growth transformation of human pancre-
atic cells is associated with increased invadopodium activity.
There appeared to be a correlation between high levels of invado-
podium formation and the presence of a mutant KRAS allele. To
determine if K-Ras expression is essential for invadopodium for-
mation, we knocked down expression of the activated KRAS allele
in PANC-1 cells (heterozygous for mutant KRAS) by stable ex-
pression of shRNA specific for this mutant sequence (9). We also
knocked down total K-Ras protein expression in MIA PaCa-2 cells
(homozygous for the mutant KRAS allele) using KRAS-specific
shRNA sequences described previously (61). Stable expression of
both shRNA constructs resulted in substantial reductions in the
K-Ras protein (Fig. 2A and B). We observed that stable suppres-
sion of endogenous K-Ras(12V) expression in PANC-1 cells and
total K-Ras expression in MIA PaCa-2 cells was associated with a
significant decrease in invadopodia (Fig. 2C to F). These results
suggest that continued expression of activated K-Ras is essential
for invadopodia in PDAC cells.
FIG 1 PDAC cells form invadopodia. Eight PDAC cell lines (seven KRAS mutant and one wild-type [WT] KRAS) were analyzed for invadopodium activity using
the in vitro matrix degradation assay. Cells were cultured for 24 h on cross-linked gelatin overlaid with Alexa Fluor 488-coupled fibronectin, fixed, and stained
with antibody against cortactin. Quantitation was conducted to determine high (more than 3 invadopodia and a percentage of invadopodium-positive cells/field
of greater than 40%), moderate (more than 1 invadopodium and a percentage of invadopodium-positive cells/field of greater than 30%), and low (0 to 1
invadopodia and a percentage of invadopodium-positive cells/field of 0 to 30%) invadopodium activity. Representative confocal images from a matrix degra-
dation assay using CFPAC-1, PANC-1, MIA PaCa-2, and T3M4 cells. Boxed areas of interest (illustrating staining of cortactin in degraded areas of the matrix)
are enlarged (2). Scale bars, 10 m. Data shown are representative of three independent experiments.
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FIG 2 Activated K-Ras growth transformation of human pancreatic cells is associated with increased invadopodium activity. Expression of K-Ras(12V)-specific shRNA
[K-Ras(12V)i] in PANC-1 cells and total K-Ras-specific shRNA (K-Rasi) in MIA PaCa-2 cells decreases invadopodium activity. (A) Western blot analysis of lysates from
PANC-1 cells expressing GFP control shRNA or K-Ras(12V)-specific shRNA. (B) Western blot analysis of lysates from MIA PaCa-2 cells expressing nonspecific (NS)
shRNA or total K-Ras-specific shRNA. (C and D) Expression of K-Ras(12V)-specific shRNA in PANC-1 cells decreases the number of invadopodia per cell (C) and the
percentage of invadopodium-positive cells (D). Statistically significant differences between GFP shRNA- and K-Ras(12V)-specific shRNA-expressing cells, as deter-
mined by a Mann-Whitney U test, are indicated by a single asterisk (P value  0.05) or three asterisks (P value  0.005). (E and F) Expression of K-Ras-specific shRNA
in MIA Paca-2 cells decreases the number of invadopodia per cell (E) and the percentage of invadopodium-positive cells (F). Statistically significant differences between
NS shRNA- and K-Ras-specific shRNA-expressing cells, as determined by a Mann-Whitney U test, are indicated by two asterisks (P value  0.01) or three asterisks (P
value0.005). (G) Western blot analysis to verify K-Ras(12D) expression in HPNE-K-Ras cells. (H) Confocal images of HPNE and HPNE-K-Ras cells. Cells were seeded
on coverslips coated with Alexa Fluor 488-coupled fibronectin and stained with antibody against cortactin. Boxed areas of interest (illustrating staining of cortactin in
degraded areas of the matrix) are enlarged (2). Scale bars, 10 m. (I and J) Expression of K-Ras(12D) increases the number of invadopodia per cell (I) and the
percentage of invadopodium-positive cells (J). Statistically significant differences between HPNE and HPNE-KRAS cells, as determined by a Mann-Whitney U test, are
indicated by two asterisks (P value  0.01) or three asterisks (P value  0.0005). Ten fields (containing 15 to 40 cells each) per condition were used for all quantitation.
Data are represented in graphs as means  standard errors of the mean (SEM). Data shown are representative of two or more independent experiments.
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Next, we determined whether expression of activated K-Ras in
normal human pancreatic duct-derived epithelial cells (HPNE) is
sufficient to induce invadopodium formation (13, 33). We
showed previously that mutant KRAS induced the tumorigenic
growth and invasion of HPNE cells (13, 43). Activated K-Ras
(12D) was stably expressed in HPNE cells (HPNE-K-Ras), and the
matrix degradation assay was performed. HPNE-K-Ras cells ex-
hibited a significant increase in invadopodia compared to control
HPNE cells (Fig. 2G to J). We conclude that mutant K-Ras is both
necessary and sufficient for invadopodium formation in PDAC
cells.
Activation of RalB is critical for invadopodium formation in
KRAS mutant PDAC cell lines. K-Ras activates multiple down-
stream signaling pathways, including the Raf-MEK-ERK cascade,
the phosphatidylinositol 3-kinase (PI3K)-Akt, and the Ral small
GTPase guanine nucleotide exchange factor (RalGEF)-Ral effec-
tor pathways (56). We next sought to investigate which down-
stream pathways were important for K-Ras-mediated invadopo-
dium activity in PDAC cell lines. It was shown previously that
ARF6 small GTPase- and transforming growth factor -mediated
invadopodium formation in melanoma and human breast cancer
cells, respectively, is dependent on ERK signaling (40, 63). We
therefore investigated whether this pathway was important for
invadopodia in PDAC cell lines and HPNE cells expressing the
activating KRAS(12D) mutant (HPNE-K-Ras). Invadopodium
activity was assessed in PANC-1, CFPAC-1, and HPNE-K-Ras
cells treated with the U0126 MEK1/MEK2-selective inhibitor.
ERK1/ERK2 phosphorylation was decreased in cells treated with
U0126 (Fig. 3A), but neither the number of invadopodia per cell
(Fig. 3B) nor the percentage of cells with invadopodia (Fig. 3C)
was decreased by inhibitor treatment. These results indicate that
the Raf effector signaling pathway does not play a significant role
in invadopodium formation in PDAC cells.
The phosphatidylinositol 3-kinase (PI3K) signaling pathway
has an established role in invadopodium formation in melanoma
(50) and breast cancer (70) cell lines. Therefore, we sought to
investigate whether treatment of PDAC cells with an inhibitor of
the PI3K pathway affected invadopodium formation. Treatment
of CFPAC-1 and PANC-1 cells with LY294002 significantly re-
duced the levels of phosphorylation of Akt on serine 473 (Fig. 3D).
This reduction in phosphorylation was accompanied by a signifi-
cant, but not complete, reduction in the number of invadopodia
per cell in CFPAC-1 cells (Fig. 3E) and in the percentage of inva-
dopodium-positive cells in both CFPAC-1 and PANC-1 cells (Fig.
3F). These data suggest that elevated basal PI3K activity is neces-
sary for invadopodium formation in PDAC cells. However, since
our previous analyses did find that pAkt levels are not associated
with mutant KRAS in PDAC cell lines (34) or patient tumors (36)
and that shRNA suppression of mutant KRAS expression did not
FIG 3 The Raf-MEK-ERK signaling pathway downstream of activated K-Ras is not required for invadopodia, but pharmacological inhibition of PI3K decreases
invadopodium activity. (A) Western blot analysis for phospho-ERK 1/2 (pERK1/2), total ERK, and vinculin of CFPAC-1, PANC-1, and HPNE-K-Ras cell lysates
following treatment with 10 M U0126 for 24 h. (B and C) Number of invadopodia per cell (B) and percentage of invadopodium-positive cells (C). (D) Western
blot analysis for phosphoserine 473 Akt (pS473 Akt), total Akt, and vinculin of CFPAC-1 and PANC-1 cell lysates following treatment with 10 M LY294002 for
24 h. (E and F) Number of invadopodia per cell (E) and percentage of invadopodium-positive cells (F). Statistically significant differences between dimethyl
sulfoxide (DMSO)- and LY294002-treated cells, as determined by a Mann-Whitney U test, are indicated by three asterisks (P value  0.005). Ten fields
(containing 15 to 40 cells each) per condition were used for all quantitation. Data are means  SEM. Data shown are representative of at least two independent
experiments.
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reduce pAkt levels (data not shown), PI3K activation may not be
through its role as a K-Ras effector.
Our previous studies established a critical role for the RalGEF-
RalB pathway in PDAC Matrigel invasion in vitro and/or metas-
tasis as determined in the tail vein lung colonization assay (36, 64).
Based on these observations, we speculated that Ral GTPases may
be involved in PDAC invadopodium formation. To determine if
expression of RalA or RalB is required for invadopodia in PDACs,
we measured invadopodium formation in cells depleted of endog-
enous RalA or RalB by using RalA- and RalB-specific shRNAs. All
four cell lines stably expressing RalB-specific shRNA showed sig-
nificant decreases in numbers of invadopodia and in the percent-
ages of invadopodium-positive cells (Fig. 4A to E). Decreases in
numbers of invadopodia were also seen in three of the four cell
lines expressing RalA-specific shRNA that were tested (Fig. 4D),
although these effects were not as significant as those seen with a
RalB knockdown. No changes were observed in the percentage of
invadopodium-positive cells in cells expressing RalA-specific
shRNA (Fig. 4E). These results suggest an essential role for RalB,
and to a lesser extent RalA, in the establishment of an invasive
phenotype.
One of the major characteristics of productive invadopodia is
the secretion and plasma membrane localization of matrix metal-
loproteinases (MMPs), including MMP-2, MMP-9, and MT1-
MMP (19, 37, 52). The exocyst plays a central role in the transport
and secretion of MMPs critical for invadopodium activity (38,
58). Because two of the major downstream effectors of activated
RalB are Sec5 and Exo84, components of the exocyst, we exam-
ined whether the secretion and activity of MMP-2 and MMP-9
were impaired in PDAC cells expressing RalB-specific shRNA.
Gelatin zymography was performed using conditioned media
from control GFP shRNA- and RalB-specific shRNA-expressing
cells. Unexpectedly, we observed no significant changes in the
secretion or activity of MMP-2 or MMP-9 (Fig. 5A). We also ex-
amined whether plasma membrane localization of the transmem-
brane protease MT1-MMP was altered in cells with RalB suppres-
sion by using surface biotinylation followed by an avidin
pulldown. Cells expressing RalB-specific shRNA showed no im-
pairment in MT1-MMP plasma membrane localization (Fig. 5B).
These data suggest that RalB does not mediate the secretion, lo-
calization, and activity of three of the major proteases involved in
invadopodium activity in tumor cells.
RalBP1 is essential for RalB-mediated invadopodium forma-
tion. To date, the best-validated effectors of Ral function are two
subunits (Sec5 and Exo84) of the octomeric exocyst complex. In
particular, Sec5-mediated activation of the TBK1 protein kinase
has been implicated in mutant KRAS-dependent promotion of
tumor cell survival (5, 17). Furthermore, both Sec5 and Exo84
have been implicated in mutant KRAS-dependent, anchorage-in-
dependent growth transformation of human cells (26). Finally,
our studies linked a third Ral effector, RalBP1/RLIP76, to RalA-
dependent PDAC anchorage-independent and tumorigenic
growth (35). That RalBP1 can function as a Rho-selective GTPase-
activating protein (RhoGAP) and as a negative regulator of Rac1
and Cdc42, both implicated previously in invadopodium activity
(32, 50, 58, 69), suggests that it may be an important effector of
RalB-mediated invadopodia. Therefore, to address possible roles
for Sec5, Exo84, and RalBP1 in RalB-dependent invadopodium
formation, we utilized two well-characterized effector binding
mutants of RalB (47, 48, 55). Introduction of a D49N point mu-
tant into the Ral core effector binding domain impairs Ral binding
to RalBP1 while retaining the ability of Ral to bind both Sec5 and
Exo84. In contrast, a D49E point mutation retains RalBP1 binding
but is impaired for both Sec5 and Exo84 binding. Both mutants
have been utilized widely to dissect Ral effector function. We
found that expression of WT RalB and RalB(D49E) in cells de-
pleted of endogenous RalB restored the ability of these cells to
form invadopodia. These results verify the specificity of the RalB
shRNA and show that the two exocyst subunits are dispensable for
RalB-induced invadopodia. In contrast, RalB(D49N) failed to res-
cue the deficiency in invadopodia caused by the suppression of
endogenous RalB expression (Fig. 6A to D). These results suggest
that RalBP1 may be a critical downstream effector necessary for
invadopodium activity in PDAC cells.
To directly determine the requirement for RalBP1 for invado-
podium formation in PDAC cells, we utilized RalBP1-specific
shRNA to suppress endogenous RalBP1 expression and analyzed
the consequences on invadopodium formation. Suppression of
endogenous RalBP1 expression using two shRNAs that target dif-
ferent RalBP1 sequences resulted in severely impaired invadopo-
dium activity in CFPAC-1 cells (Fig. 7A to D). When taken to-
gether with the results from rescue experiments with RalB effector
binding mutants, our analyses support a key role for RalBP1 as the
critical RalB effector in this process.
Although RalBP1 is a multidomain protein with diverse bio-
chemical functions, its best known function is as a Rho-selective
GTPase-activating protein (RhoGAP) and negative regulator of
Cdc42 and Rac1 (14, 29, 54). Because Cdc42 is known to play an
important role in invadopodium formation (50, 58), we investi-
gated whether the GAP activity of RalBP1 is required for its role in
invadopodium activity in PDAC cells. We generated a GAP-defi-
cient mutant by introducing missense mutations in the arginine
finger (R232) and the conserved lysine residue (K268) in the GAP
catalytic domain of human RalBP1. We tested the ability of bac-
terially expressed wild-type and R232A/K268A RalBP1 GAP do-
mains (amino acids [aa] 124 to 468) (Fig. 8A and B) to stimulate
the intrinsic GTP hydrolysis activity of Cdc42 using a fluorescent-
conjugated phosphate-binding protein assay (60). The presence of
purified wild-type RalBP1 stimulated the intrinsic GTP hydrolysis
of Cdc42, while the presence of an equivalent concentration of
R232A/K268A RalBP1 failed to enhance hydrolysis (Fig. 8C).
We then generated HA-tagged, full-length wild-type and R232A/
K268A RalBP1 RNAi-insensitive mammalian expression constructs
to determine whether the role of RalBP1 in invadopodium formation
was dependent on its catalytic GAP activity. We were unable to gen-
erate CFPAC-1 RalBP1 interference (RalBP1i) cells stably expressing
the RK/AA RalBP1 mutant due to lethality, which was perhaps due to
a dominant negative phenotype. Therefore, invadopodium activity
was quantitated in transiently infected cells. HA epitope-tagged wild-
type or R232A/K268A RalBP1-infected cells were identified by im-
munofluorescence staining with an anti-HA antibody. Only cells
staining positive for HA were used for quantitation. We found that
restoration of wild-type RalBP1 expression rescued impairment in
invadopodium activity in cells expressing RalBP1-specific shRNA,
demonstrating the specificity of the RalBP1 shRNA (Fig. 8D to F).
Surprisingly, expression of GAP-deficient RalBP1(R232A/K268A)
also rescued the loss of endogenous RalBP1. To verify that the role of
RalBP1 in invadopodium activity was indeed GAP independent,
we examined whether a previously validated GAP-deficient
RalBP1 mutant (8) would also rescue the invadopodium defi-
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FIG 4 RalB plays a more predominant role than RalA in invadopodium formation in human KRAS mutant PDAC cell lines. (A) Western blot analysis of lysates
from indicated cell types stably expressing RalB-specific (RalBi), RalA-specific (RalAi), or control GFP (GFPi) shRNA. Confocal images of CFPAC-1 (B) and
PANC-1 (C) cells stably expressing RalB-specific (RalBi) or GFP (GFPi) shRNA seeded on coverslips coated with Alexa Fluor 488-coupled fibronectin and stained
with anticortactin antibody. Boxed areas of interest (illustrating staining of cortactin in degraded areas of the matrix) are enlarged (2). Scale bars, 10 m. (D)
The number of invadopodia per cell is decreased in cells expressing RalB-specific shRNA. (E) The percentage of invadopodium-positive cells is decreased more
significantly in cells expressing RalB-specific shRNA. Ten fields (containing 15 to 40 cells each) per condition were used for all quantitation. Statistically
significant differences between RalB shRNA or RalA shRNA and GFP shRNA cells, as determined by a Mann-Whitney U test, are indicated by one (P value 
0.05), two (P value  0.01), or three (P value  0.005) asterisks. Data are means  SEM. Data shown are representative of three independent experiments.
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ciency in cells expressing RalBP1-specific shRNA. We stably ex-
pressed an R208L/K244R (RK/LR) RalBP1 RNAi-insensitive ex-
pression construct in RalBP1 shRNA-expressing CFPAC-1 cells.
Expression of the RK/LR mutant protein also rescued the invado-
podium-deficient phenotype in RalBP1i cells (Fig. 8G to I). These
results demonstrate a GAP-independent role for RalBP1 in inva-
dopodium formation in PDAC cells.
RalBP1 ATP-binding mutants fail to rescue invadopodium
defects in cells expressing RalBP1 shRNA. Another well-estab-
lished role of RalBP1 is its function as an ATP-binding plasma
membrane transporter pump (2, 3, 62). RalBP1 contains two val-
idated ATP-binding sites at residues 69 to 74 and 418 to 425 (2).
Mutation of lysines 74 and 425 to methionine in recombinant
RalBP1 N and C terminus peptides impaired RalBP1 binding to
ATP and ATPase activity (2). We sought to investigate whether the
ATPase function of RalBP1 was important for its role in support-
ing invadopodium formation. RalBP1 variants containing the
K74M, K425M, or combined K74M/K425M mutations were gen-
erated, stably expressed in RalBP1 shRNA-expressing cells, and
evaluated for their ability to rescue the loss of endogenous RalBP1.
The K425M mutant, either alone or in combination with the
K74M mutation, failed to rescue the invadopodium defects in cells
expressing RalBP1 shRNA (Fig. 9A to C). These results suggest
that ATP binding to RalBP1, and perhaps its plasma membrane
transport role, is essential for invadopodia in PDAC cells.
DISCUSSION
Although the best-studied effector pathways of Ras are those in-
volving Raf or PI3K, there is greater appreciation that the depen-
dency of human tumor cells on mutant KRAS must involve addi-
tional effectors (39, 59, 61). In support of this possibility, our
recent studies suggest that the RalGEF effector pathway, rather
than the Raf or PI3K effector pathway, may be a major mediator of
KRAS-dependent PDAC growth (34). Although RalGEF leads to
FIG 5 RalB suppression and impaired invadopodium formation are not as-
sociated with reduced MMP-2/MMP-9 gelatinase activity or MT1-MMP
plasma membrane localization. (A) Representative zymograms from 24-h-
conditioned medium showing secreted MMP-2 and MMP-9. (B) Representa-
tive Western blot analysis of MT1-MMP in input lysates and avidin pulldown
following surface biotinylation in CFPAC-1 cells stably expressing control GFP
(GFPi) or RalB-specific shRNA (RalBi). Data shown are representative of two
independent experiments.
FIG 6 RalB D49N effector mutant with impaired RalBP1 binding fails to rescue invadopodium formation in PDAC cells expressing RalB-specific shRNA.
Western blot analysis of lysates from CFPAC-1 (A) and PANC-1 (B) cells expressing GFP shRNA (GFPi), RalB-specific shRNA (RalBi), and either an empty
vector or wild-type (WT), D49E, or D49N RalB. (C) Number of invadopodia per cell. (D) Percentage of invadopodium-positive cells per field. Ten fields
(containing 15 to 40 cells each) per condition were used for all quantitation. Statistically significant differences between RalB-specific shRNA/vector and
RalB-specific shRNA/WT or D49E RalB cells, as determined by a Mann-Whitney U test, are indicated by an asterisk (P value  0.005). Data are means  SEM.
Data shown are representative of three independent experiments.
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activation of the highly related RalA and RalB proteins, there is
now considerable evidence that they each serve distinct roles in
oncogenesis (7, 51). For PDAC, we found that RalB was dispens-
able for anchorage-independent and tumorigenic growth and in-
stead was important for invasion and metastasis. To further ex-
plore the signaling mechanisms that drive PDAC invasion and
metastasis, we first determined that PDAC tumor cells form inva-
dopodia, plasma membrane protrusions that promote matrix
degradation, and that their formation was dependent on mutant
KRAS function. We then found that this activity was dependent on
RalB, and to a lesser extent RalA, and not the Raf effector pathway.
Surprisingly, RalB-mediated invadopodium formation was not
dependent on exocyst regulation and instead was dependent on a
RhoGAP-independent function of the RalBP1 effector.
Previous studies have described invadopodium formation for
Src-transformed cells and a variety of human cancers, in particu-
lar, breast carcinoma, melanoma, and glioblastoma. Our studies
provide the first description of invadopodia in PDAC and its as-
sociation with K-Ras. The six cell lines that showed moderate to
high invadopodium activity possessed activating KRAS muta-
tions, suggesting a correlation between KRAS mutation status and
invadopodium activity. We conclude that invadopodia are a com-
mon feature of PDAC cells, thus expanding the spectrum of hu-
man cancers for which they may contribute to invasive and ma-
lignant growth. The essential roles of mutationally activated
K-Ras in initiation and progression in the early stages of pancre-
atic cancer are well established. However, our results suggest that
oncogenic K-Ras can additionally promote the invasive pheno-
type that occurs later in tumor progression. One mechanism by
which this may be achieved is a switch in K-Ras effector utilization
at different stages of tumor progression. Recently, we described
such a mechanism where Ras can switch from use of Raf to use of
RalGEF, leading to changes in Ras-driven cell fate (71). Finally,
whether a K-Ras-dependent induction of invadopodia will be seen
in other human cancers (lung and colorectal) with frequent KRAS
mutations is important to determine.
Our data strongly implicate the RalB-mediated signaling path-
way downstream of K-Ras and suggest the absence of a role for the
MAPK pathway. In contrast, there appears to be a clear role for the
PI3K signaling pathway in PDAC invadopodium activity based on
our inhibitor studies. However, there is no definitive association
between KRAS mutation status and activation of the PI3K path-
way in PDAC cells. This is illustrated by our previous data showing
that pS473 Akt levels are not elevated in human PDAC cell lines
(34) or patient tumors (36). In addition, a recent study identified
the frequent coexistence of KRAS and PIK3CA mutations in mul-
tiple advanced-stage cancers (27), suggesting that the PI3 kinase
pathway may function independently of K-Ras activation.
Our implication of K-Ras and RalB in PDAC invadopodium
formation extends the repertoire of small GTPases associated with
this process. Previous studies have implicated Rho, Rac, Cdc42,
and Wrch-1 Rho family small GTPases in cytoskeleton-associated
processes and Arf6 in transport processes that are associated with
invadopodia (22, 32, 49, 50, 58, 63, 69). It is essential to determine
whether RalB is also important for invadopodium activity in
breast, melanoma, and other cancers to assess whether RalB-de-
pendent invadopodium formation is unique for PDAC or shared
with other cancers.
Our finding that RalB, to a greater extent than RalA, is required
for invadopodium formation is consistent with our previous de-
termination of a more critical role of RalB in PDAC invasion and
metastasis. However, what was unexpected was our determina-
tion of the effectors that mediate RalB function. Since secretion of
proteases is a key property of invadopodia, we anticipated that the
Sec5 and Exo84 subunits of the exocyst would be required. Previ-
FIG 7 RalBP1 is required for PDAC cell invadopodium formation. (A) West-
ern blot analysis of lysates from CFPAC-1 cells expressing nonspecific (NS)
shRNA or shRNA clones directed against RalBP1 (RalBP1i). Clones 20 and 22
exhibited the most efficient knockdown of protein by Western blot and were
chosen for further analyses. (B) Representative confocal images of CFPAC-1
cells expressing NS shRNA or RalBP1-specific shRNA clone 22. Cells were
seeded on coverslips coated with Alexa Fluor 488-coupled fibronectin and
stained for cortactin. Boxed areas of interest (illustrating staining of cortactin
in degraded areas of the matrix) are enlarged (2). Scale bars, 10 m. (C)
Number of invadopodia per cell. (D) Percentage of invadopodium-positive
cells per field. Ten fields (containing 15 to 40 cells each) per condition were
used for all quantitation. Statistically significant differences between NS
shRNA- and RalBP1-specific shRNA-expressing cells, as determined by a
Mann-Whitney U test, are indicated by an asterisk (P value  0.005). Data are
means  SEM. Data shown are shown are representative of two independent
experiments.
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FIG 8 RalBP1 supports PDAC invadopodium formation through a GAP-independent mechanism. (A) Schematic of the domains of bacterially purified RalBP1 used
in the GAP activity assay. (B) Representative Coomassie brilliant blue-stained gel of purified wild-type (WT) and R232A/K268A (RK/AA) RalBP1. (C) Real-time GTP
hydrolysis rate of 2 M purified GTP-loaded Cdc42 alone (no GAP) or in the presence of 1 M WT or RK/AA RalBP1. (D) Western blot analysis of CFPAC-1 cells stably
expressing GFP (GFPi) or RalBP1-specific shRNA (RalBP1i) and transiently expressing either empty vector or HA-tagged WT or RK/AA (GAP-deficient) RalBP1. (E)
Number of invadopodia per cell. (F) Percentage of invadopodium-positive cells. Twenty fields (containing 15 to 40 cells each) per condition were used for quantitation,
and only HA-positive cells were counted. Statistically significant differences between cells stably expressing RalBP1 shRNA and empty vector and either GFP shRNA and
empty vector, RalBP1 shRNA and WT RalBP1, or RalBP1 shRNA and RK/AA RalBP1, as determined by a Mann-Whitney U test, are indicated by an asterisk (P  0.005).
(G) Western blot analysis of CFPAC-1 cells stably expressing GFP or RalBP1-specific shRNA and stably expressing either empty vector or HA-tagged WT or R208L/
K244R (RK/LR) (GAP-deficient) RalBP1. (H) Number of invadopodia per cell. (I) Percentage of invadopodium-positive cells. Ten fields (containing 15 to 40 cells each)
per condition were used for quantitation. Statistically significant differences between cells stably expressing RalBP1 shRNA and empty vector and either GFP shRNA and
empty vector, RalBP1 shRNA and WT RalBP1, or RalBP1 shRNA and RK/LR RalBP1, as determined by a Mann-Whitney U test, are indicated by an asterisk (P  0.005).
Data are means  SEM. Data shown are representative of three independent experiments.
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ously, the Sec3, Exo70, and Sec8 exocyst subunits were shown to
be required for invadopodium formation in KRAS mutant MDA-
MB-231 breast carcinoma cells, primarily for MMP regulation
and matrix degradation (38, 58). However, our finding that exo-
cyst binding was not required for RalB function is consistent with
our result that RalB suppression did not reduce MMP protease
activity in PDAC. Perhaps non-Ral-dependent mechanisms that
regulate exocyst function and MMP secretion are involved in
PDAC invadopodia. Finally, our exclusion of the importance of
Sec5 and Exo84 from RalB function contrasts with the majority of
other reported functions of RalB, including regulation of cytoki-
nesis (15), innate immunity (17), or the cellular starvation re-
sponse (6), in which exocyst subunit function was found to be
essential.
In light of the established involvement of Rac and Cdc42 in
invadopodia, our finding that the RalBP1 requirement for RalB-
mediated invadopodium formation is largely RhoGAP indepen-
dent was unexpected. This result differs from our finding that
RalA-dependent PDAC growth was dependent on RalBP1 and
involved negative regulation of Rac and Cdc42 function (35).
However, RalBP1 is a large multidomain protein with a variety of
other functions mediated through interactions with a spectrum of
functionally distinct proteins. Instead, we found that an ATPase-
deficient mutant of RalBP1 was drastically impaired in its ability
to rescue the loss of endogenous RalBP1 and restore invadopo-
dium activity. The ATP binding and ATPase activity of RalBP1
have been reported to be required for RalBP1 function as a non-
ABC transporter of structurally divergent molecules, including
chemotherapeutic drugs, out of cells (1, 2). Interestingly, while the
K425 residue of the C-terminal ATP-binding motif does not di-
rectly overlap the Ral-GTP binding domain of RalBP1, it is spec-
ulated that the RalB-GTP association may regulate ATP binding
(20). Whether it is this function as a transporter that is essential for
RalBP1 function in invadopodium formation and whether this
function is regulated by RalB binding are important future issues
to resolve.
RalBP1 is also known to associate with several proteins in-
volved in endocytosis, including the 2 subunit of the clathrin
adaptor complex AP-2 (30), activin receptor-interacting protein 2
(ARIP2) (44), partner of RalBP1 (POB1) (46), and Reps1 (68).
RalBP1 is involved in stress responses and mitosis through its
interactions with heat shock factor 1 (HSF-1) (24) and Cdk1 (57),
respectively. The multidomain structure of RalBP1 links it to a
number of physiological roles within the cell that may be impor-
tant for invadopodia. Putative membrane association domains
were previously identified for RalBP1 (67). In addition, active Ral
can recruit RalBP1 to the membrane (42), and it is likely that this
localization is important for its function in invadopodia. RalBP1
serves as an endocytic adaptor protein (25, 30, 68), and it is likely
to play a scaffolding role in other cellular processes, including
perhaps invadopodia. Future detailed mutagenesis analyses of
RalBP1 will be required to identify the function(s) essential for
invadopodium formation in PDAC cells.
In summary, our studies implicate for the first time the impor-
tance of the aberrant activation of K-Ras and the downstream Ral
effector signaling pathway for invadopodium activity in pancre-
atic cancer cells. Specifically, we demonstrate that RalB is neces-
sary for invadopodium function through its effector RalBP1. In-
terestingly, we show that RalBP1 regulates invadopodium activity
in a GAP-independent manner. Further elucidation of the mech-
anism by which RalBP1 promotes invadopodia may define novel
directions for therapeutic strategies for metastatic PDAC. In sum-
mary, while the Src oncoprotein and Rho GTPases are well-char-
acterized regulators of invadopodia, our delineation of a K-Ras-
FIG 9 RalBP1 ATP-binding mutants fail to rescue invadopodium defects in cells expressing RalBP1 shRNA. (A) Western blot analysis of CFPAC-1 cells stably
expressing GFP (GFPi) or RalBP1-specific shRNA (RalBP1i) and stably expressing either empty vector or HA-tagged WT, K74M, K425M, or K74M/K425M
RalBP1. (B) Number of invadopodia per cell. (C) Percentage of invadopodium-positive cells. Ten fields (containing 15 to 40 cells each) per condition were used
for quantitation. Statistically significant differences between the groups within the brackets, as determined by a Mann-Whitney U test, are indicated by one (P
value  0.01) or two (P value  0.005) asterisks. Data are means  SEM. Data shown are representative of three independent experiments.
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and RalB-mediated mechanism defines a novel signaling mecha-
nism for invadopodium formation.
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